Team 2: Nuclear Oncology
Team 2 Leaders : Pr. Michel Chérel & Pr Françoise Kraeber-Bodéré
Our research aims to develop diagnostic and therapeutic tools to fight cancer by focusing on the delivery of radionuclides to cancer cells and their biological effects.
Fundings/Networks
 |
 |
 |
||
 |
 |
 |
 |
 |
 |
 |
Platforms
|
|
 |
Our social media
Latest publications
- Jamet B. et al. Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact. Leukemia (2025). https://doi.org/10.1038/s41375-025-02717-0
- Maingueneau C. et al. Bambusuril as an effective astatide sequestrating agent by hydrogen bonding. Chem. Comm. (2025). https://doi.org/10.1039/d5cc02762d
- Fouinneteau R. et al. Ortho-functionalization of a 211At-labeled aryl compound provides stabilization of the C-At bond against oxidative dehalogenation. Sci. Rep. (2025). https://doi.org/10.1038/s41598-025-01162-4
With the identification of numerous relevant biomarkers, nuclear medicine offers innovative approaches for precision therapeutics and theranostics in oncology, using radiolabeled antibodies or other vectors. Our team gathers working groups with all the competences required to design new radiopharmaceuticals and validate them from preclinical to clinical evaluations, especially immuno-PET and targeted radionuclide therapy (TRT), especially using alpha emitters. This translational research requires a pluridisciplinary expertise going from the extraction of the radionuclides to the preparation of the radiopharmaceuticals.
Originally investigating radiolabeled antibodies to treat cancer and hemopathies, over the past 5 years we have been moving forward to developing a research in molecular imaging, especially PET, innovative PET emitters being now available for imaging tumor phenotype, in particular with radiolabeled mAbs (immuno-PET) through theranostic approaches. Biomarker imaging using immuno-PET represents also a promising tool to predict efficacy of targeted therapies (precision therapeutics based on predictive imaging or companion diagnostic) or to predict patient outcome (prognostic imaging and radiomics). Development of radiopharmaceuticals relies on a fundamental and forward thinking on radionuclides, targets, new vectors and requires to develop pertinent animal models (murine, canine) before clinical development, but also requires expertise in quantitative imaging. Each specific field including radiopharmacy, chemistry/radiochemistry, radiobiology and immunology is developing its own work and projects towards a common goal. Our pluridisciplinary research is integrated in the personalized/stratified medicine, tumor targeting with innovative α, β- and β+ radionuclides allowing a predictive whole-body imaging which is complementary to metabolic (PET using FDG) and morphologic (CT and MRI) imaging as well as image guided innovative targeted therapies (quantitative imaging, dosimetry, radiomics).
There is currently no open position in the group. Please come back soon !
- Jamet B. et al. Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact. Leukemia (2025). https://doi.org/10.1038/s41375-025-02717-0
- Maingueneau C. et al. Bambusuril as an effective astatide sequestrating agent by hydrogen bonding. Chem. Comm. (2025). https://doi.org/10.1039/d5cc02762d
- Maingueneau C. et al. Preparation of 211At-Labeled (Hetero)aryl Compounds from Triarylsulfonium and Dibenzothiophenium Salts. Org. Lett. (2025). https://doi.org/10.1021/acs.orglett.5c02074
- Fouinneteau R. et al. Ortho-functionalization of a 211At-labeled aryl compound provides stabilization of the C-At bond against oxidative dehalogenation. Sci. Rep. (2025). https://doi.org/10.1038/s41598-025-01162-4
- Ligeour M. et al. Formation Of Gold-Astatine Bonds in N-Heterocyclic Carbene Complexes. Chem. Eur. J (2025). https://doi.org/10.1002/chem.202500826
- Peterlin P. et al, FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies. Haematologica (2025). https://doi.org/10.3324/haematol.2024.28602
- Rousseau, C. et al. Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [211At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care. Cancers (2025). https://doi.org/10.3390/cancers17071190
- Vanermen, M. et al. Astatine-211 radiolabelling chemistry: from basics to advanced biological applications. EJNMMI radiopharm. chem. (2024). https://doi.org/10.1186/s41181-024-00298-4
- Lugat, A., et al. Survival impact of [225Ac]Ac-DOTATOC alpha-therapy in a preclinical model of pancreatic neuroendocrine tumor liver micrometastases. Eur J Nucl Med Mol Imaging (2024). https://doi.org/10.1007/s00259-024-06918-0
- Ludovic Le Saux et al. Sydnone-based prosthetic groups for radioiodination, Bioorg. Med. Chem. (2024). https://doi.org/10.1016/j.bmc.2024.117904.
- Loris Roncali, et al. Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice, eBioMedicine (2024). https://doi.org/10.1016/j.ebiom.2024.105202.
- Métivier C., et al. Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma. Pharmaceutics. 2023, 15(7), 1817; https://doi.org/10.3390/pharmaceutics15071817
- Perrin J, Capitao M, Allard M , Chouin N , Gouard S, Marionneau-Lambot S, Louvet C, Donnadieu E, Bruchertseifer F, Morgenstern A, Chérel M, Gaschet J, Guilloux Y. Targeted alpha particle therapy remodels the tumor microenvironment and improves efficacy of immunotherapy. Int J Radiat Oncol Biol Phys. 2022;112(3):790-801. doi: 10.1016/j.ijrobp.2021.10.013.
- Maingueneau C, Berdal M, Eychenne R, Gaschet J, Chérel M, Gestin JF, Guérard F. 211At and 125I-Labeling of (Hetero)Aryliodonium Ylides: Astatine Wins Again. Chemistry. 2022;28(11):e202104169. doi: 10.1002/chem.202104169.
- Alberge JB, Kraeber-Bodéré F, Jamet B, Touzeau C, Caillon H, Wuilleme S, Avet-Loiseau H, Corre J, Magrangeas F, Carlier T, Bodet-Milin C, Chérel M, Moreau P, Minvielle S, Bailly C. Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study. J Nucl Med. 2022 Jan 27:jnumed.121.262884. doi: 10.2967/jnumed.121.262884. [Online ahead of print]
- Delage JA, Gnesin S, Prior JO, Barbet J, Le Saëc P, Marionneau-Lambot S, Gouard S, Chérel M, Bourgeois M, Schaefer N, Viertl D, Fierle JK, Dunn SM, Faivre-Chauvet A. Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety. Cancers. 2021;13(23):5936. doi: 10.3390/cancers13235936.
- Bodet-Milin C, Faivre-Chauvet A, Carlier T, Ansquer C, Rauscher A, Frampas E, Toulgoat F, Masson D, Bourgeois M, Cerato E, Rohmer V, Couturier O, Drui D, Goldenberg DM, Sharkey RM, Barbet J, Kraeber-Bodere F. Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study. J Nucl Med. 2021;62(9):1221-1227. doi: 10.2967/jnumed.120.252791.
- Guérard F, Maingueneau C, Liu L, Eychenne R, Gestin JF, Montavon G, and Galland N. Advances in the Chemistry of Astatine and Implications for the Development of Radiopharmaceuticals. Acc. Chem. Res. 2021, 54, 3264−3275. doi: 10.1021/acs.accounts.1c00327.
- Jamet B, Morvan L, Nanni C, Michaud AV, Bailly C, Chauvie S, Moreau P, Touzeau C, Zamagni E, Bodet-Milin C, Kraeber-Bodéré F, Mateus D, Carlier T. Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. Eur J Nucl Med Mol Imaging. 2021;48(4):1005-1015. doi: 10.1007/s00259-020-05049-6.
- Capitao M, Perrin J, Simon S, Gouard S, Chouin N, Bruchertseifer F, Morgenstern A, Rbah‐Vidal L, Chérel M, Scotet E, Labarrière N, Guilloux Y and Gaschet J. Anti‐Tumor Efficacy of PD‐L1 Targeted Alpha‐Particle Therapy in a Human Melanoma Xenograft Model. Cancers. 2021;13(6):1256. doi: 10.3390/cancers13061256.